Introduction India’s T2D population carries a substantial burden-nearly two-thirds of individuals with T2D are overweight or obese, indicating a significant cardio-metabolic risk burden (1).
New research shows that GLP‑1 drugs, known for helping with weight loss and blood sugar control, may offer surprising additional health benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results